Unidad de Trastornos del Movimiento, Servicio de Neurología Y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n. 41013, Seville, Spain.
Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain.
Sci Rep. 2020 Oct 9;10(1):16893. doi: 10.1038/s41598-020-73756-z.
The study was aimed at analysing the frequency of impulse control disorders (ICDs) and compulsive behaviours (CBs) in patients with Parkinson's disease (PD) and in control subjects (CS) as well as the relationship between ICDs/CBs and motor, nonmotor features and dopaminergic treatment in PD patients. Data came from COPPADIS-2015, an observational, descriptive, nationwide (Spain) study. We used the validated Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) for ICD/CB screening. The association between demographic data and ICDs/CBs was analyzed in both groups. In PD, this relationship was evaluated using clinical features and treatment-related data. As result, 613 PD patients (mean age 62.47 ± 9.09 years, 59.87% men) and 179 CS (mean age 60.84 ± 8.33 years, 47.48% men) were included. ICDs and CBs were more frequent in PD (ICDs 12.7% vs. 1.6%, p < 0.001; CBs 7.18% vs. 1.67%, p = 0.01). PD patients had more frequent previous ICDs history, premorbid impulsive personality and antidepressant treatment (p < 0.05) compared with CS. In PD, patients with ICDs/CBs presented younger age at disease onset, more frequent history of previous ICDs and premorbid personality (p < 0.05), as well as higher comorbidity with nonmotor symptoms, including depression and poor quality of life. Treatment with dopamine agonists increased the risk of ICDs/CBs, being dose dependent (p < 0.05). As conclusions, ICDs and CBs were more frequent in patients with PD than in CS. More nonmotor symptoms were present in patients with PD who had ICDs/CBs compared with those without. Dopamine agonists have a prominent effect on ICDs/CBs, which could be influenced by dose.
这项研究旨在分析帕金森病(PD)患者和对照组(CS)中冲动控制障碍(ICD)和强迫行为(CB)的频率,以及 ICD/CB 与 PD 患者的运动、非运动特征和多巴胺能治疗之间的关系。数据来自于 2015 年 COPPADIS 的一项观察性、描述性的全国性(西班牙)研究。我们使用经过验证的帕金森病冲动-强迫障碍问卷评分量表(QUIP-RS)对 ICD/CB 进行筛查。在两组中都分析了人口统计学数据与 ICD/CB 之间的关联。在 PD 中,使用临床特征和与治疗相关的数据评估这种关系。结果,纳入了 613 名 PD 患者(平均年龄 62.47±9.09 岁,59.87%为男性)和 179 名 CS(平均年龄 60.84±8.33 岁,47.48%为男性)。PD 患者中 ICDs 和 CBs 的发生率更高(ICDs 为 12.7%比 1.6%,p<0.001;CBs 为 7.18%比 1.67%,p=0.01)。与 CS 相比,PD 患者有更多的 ICD 病史、前冲动人格和抗抑郁治疗史(p<0.05)。在 PD 中,有 ICD/CB 的患者疾病发病年龄较小,更常见 ICD 病史和前冲动人格(p<0.05),并且与非运动症状(包括抑郁和生活质量差)的共病率更高。多巴胺能激动剂治疗增加了 ICD/CB 的风险,且与剂量有关(p<0.05)。总之,PD 患者的 ICDs 和 CBs 比 CS 更常见。与无 ICD/CB 的 PD 患者相比,有 ICD/CB 的 PD 患者有更多的非运动症状。多巴胺能激动剂对 ICD/CB 有显著影响,其可能受剂量影响。